Coca-Cola European Partners PLC (CCEP)vsNovo Nordisk A/S (NVO)
CCEP
Coca-Cola European Partners PLC
$94.57
+1.14%
CONSUMER DEFENSIVE · Cap: $41.40B
NVO
Novo Nordisk A/S
$46.07
+0.59%
HEALTHCARE · Cap: $202.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 1468% more annual revenue ($327.80B vs $20.90B). NVO leads profitability with a 37.2% profit margin vs 9.3%. CCEP appears more attractively valued with a PEG of 2.64. NVO earns a higher WallStSmart Score of 74/100 (B).
CCEP
Buy59
out of 100
Grade: C
NVO
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-64.8%
Fair Value
$59.24
Current Price
$94.57
$35.33 premium
Intrinsic value data unavailable for NVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 68.3% YoY
Every $100 of equity generates 23 in profit
Generating 1.5B in free cash flow
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 71 in profit
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 61.6%
Earnings expanding 67.1% YoY
Areas to Watch
0.2% revenue growth
Distress zone — elevated risk
Elevated debt levels
Weak financial health signals
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CCEP
The strongest argument for CCEP centers on EPS Growth, Return on Equity, Free Cash Flow.
Bull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.
Bear Case : CCEP
The primary concerns for CCEP are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
CCEP profiles as a value stock while NVO is a growth play — different risk/reward profiles.
CCEP carries more volatility with a beta of 0.49 — expect wider price swings.
NVO is growing revenue faster at 24.0% — sustainability is the question.
NVO generates stronger free cash flow (12.0B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (74/100 vs 59/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Coca-Cola European Partners PLC
CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA
Coca-Cola Europacific Partners PLC produces, distributes and sells a variety of ready-to-drink non-alcoholic beverages. The company is headquartered in Uxbridge, the United Kingdom.
Visit Website →Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other BEVERAGES - NON-ALCOHOLIC Stocks
Want to dig deeper into these stocks?